AGIO - NASDAQ

Agios Pharmaceuticals, Inc.

AGIO·NASDAQ

$27.68

-1.1%

HealthcareBiotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.65B

EPS-7.1200

P/E Ratio-3.89

Earnings Date07/30/2026

agio

Net Debt Issuance

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Agios Pharmaceuticals, Inc. Competitors Analysis of Net Debt Issuance

AGIO · NASDAQ

Company	Net Debt Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	0.00	N/A	N/A	N/A
Beam Therapeutics Inc. NASDAQ:BEAM	0.00	N/A	N/A	N/A
Cogent Biosciences, Inc. NASDAQ:COGT	215.13M	N/A	N/A	N/A
Sarepta Therapeutics, Inc. NASDAQ:SRPT	-162.59M	N/A	N/A	N/A
89bio, Inc. NASDAQ:ETNB	9.35M	46.7%	-14.1%	N/A
ImmunityBio, Inc. NASDAQ:IBRX	1.72M	-81.2%	-65.2%	N/A
Liquidia Corporation NASDAQ:LQDA	53.82M	40.6%	N/A	25.3%
Denali Therapeutics Inc. NASDAQ:DNLI	-8.17M	N/A	N/A	N/A
Arcus Biosciences, Inc. NYSE:RCUS	49.00M	N/A	57.9%	N/A
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	-8.43M	N/A	N/A	N/A

Agios Pharmaceuticals, Inc. Fair Value Envelope

AGIO · NASDAQ

Our analysis suggests that AGIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.68, this represents a potential HIDDEN relative to our calculated worth for Agios Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $27.68

Related Guides

Blog Categories

Continue your AGIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.